Notably, variations in pharmacokinetic profiles between obese individuals and those with NAFLD have been documented extensively, as evidenced by prior studies.[22] BBR, with its heightened retention in the liver, potentiates an additional pharmacological effect—PPARγ agonism. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.